LBRX — LB PHARMACEUTICALS INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1691082 ·
Last close
$37.22
Market Cap
$1.20B
52W High
$50.16
52W Low
$14.32
ADV30
364,643
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -53,915,000 | -51,603,000 | 361,692,000 | 283,111,000 | 29,345,000 |
| Mar 2026 | 0 | — | -22,104,000 | -19,054,000 | 393,482,000 | 320,676,000 | 14,789,000 |
| Dec 2025 | 0 | — | -13,870,000 | -11,472,000 | 312,934,000 | 250,173,000 | 11,624,000 |
| Sep 2025 | 0 | — | -5,246,000 | -3,556,000 | 320,746,000 | 269,744,000 | 10,525,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-50,370,000
Investing CF
$-44,899,000
Financing CF
$396,393,000
CapEx
$-331,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.97
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-148,582,000
Inventory
—
Receivables
—
ST Investments
$44,960,000
EBIT TTM
$-46,079,000
Pretax Income TTM
$-38,952,000
Interest Exp TTM
—
Analysts
8
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -30,404,000 | -25,205,000 | 312,934,000 | 11,624,000 | 301,310,000 | -35,208,000 |
| Dec 2024 | 0 | -64,830,000 | -63,102,000 | 33,534,000 | 128,088,000 | -94,554,000 | -53,052,000 |
| Dec 2023 | 0 | -11,376,000 | -6,275,000 | 45,657,000 | 80,130,000 | -34,473,000 | -12,094,000 |
| Dec 2022 | 0 | -2,809,000 | -14,348,000 | 21,492,000 | 50,304,000 | -28,812,000 | -2,728,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$393,482,000
Forward EPS
$-5.04
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NBTX | Nanobiotix S.A. | $1.20B | $23.68 | — |
| TYRA | Tyra Biosciences, Inc. | $1.19B | $19.94 | — |
| ORIC | Oric Pharmaceuticals, Inc. | $1.24B | $11.99 | — |
| BCAX | Bicara Therapeutics Inc. | $1.16B | $17.50 | — |
| AVLN | Avalyn Pharma Inc. | $1.14B | $25.76 | — |
News headlines (Yahoo Finance, 1h cache)
LB Pharmaceuticals Reports Inducement Grants to New Employee Under Nasdaq Listing Rule 5635(c)(4)
2026-10-09 20:42 · Yahoo
LB Pharmaceuticals to Host In-Person and Virtual R&D Day on October 27, 2026: Advancing LB‑102 with a Focus on Schizophrenia Treatment
2026-10-06 12:00 · Yahoo
IPO Stock LB Pharma Has Tripled In Under A Year. Is It A Takeover Target?
2026-09-09 12:00 · Yahoo
2 Reasons LB Pharmaceuticals (LBRX) Looks Pricey Following Its CFO Appointment
2026-09-04 10:15 · Yahoo
LB Pharmaceuticals to Participate in Upcoming September Investor Events
2026-09-03 20:05 · Yahoo
LB Pharmaceuticals Appoints Joseph Miller as Chief Financial Officer
2026-09-03 12:00 · Yahoo
LB Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-08-11 12:00 · Yahoo
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
2026-07-10 20:38 · Yahoo
LB Pharmaceuticals Inc. (LBRX) Maintains Buy Rating as Analyst Highlights LB-102 Potential
2026-07-02 20:06 · Yahoo
LB Pharmaceuticals Appoints Christopher Zergebel as Senior Vice President, Clinical Operations
2026-06-30 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.